Glycosylation as a tool for rational vaccine design.
Vivek HariharanRavi S KanePublished in: Biotechnology and bioengineering (2020)
The discovery of broadly neutralizing antibodies that can neutralize multiple strains or subtypes of a pathogen has renewed interest in the development of broadly protective vaccines. To that end, there has been an interest in designing immunofocusing strategies to direct the immune response to specific, conserved regions on antigenic proteins. Modulation of glycosylation is one such immunofocusing strategy; extensive glycosylation is often exploited by pathogens for immune evasion. Masking epitopes on protein immunogens with "self" glycans can also shield the underlying protein surface from humoral immune surveillance. We review recent advances in applying glycosylation as an immunofocusing tool. We also highlight recent interesting work in the HIV-1 field involving the identification and elicitation of broadly neutralizing antibodies that incorporate glycans into their binding epitopes.
Keyphrases
- immune response
- antiretroviral therapy
- public health
- small molecule
- binding protein
- dengue virus
- protein protein
- human immunodeficiency virus
- escherichia coli
- hiv positive
- hiv infected
- hepatitis c virus
- transcription factor
- amino acid
- cell surface
- high throughput
- candida albicans
- gram negative
- antimicrobial resistance
- multidrug resistant
- hiv aids
- single cell